Tag: Valbiotis

Valbiotis Reveals Positive TOTUM•854 Preclinical Results in the Prevention of Hypertension at the Annual ESH-ISH Joint Meeting

An acceleration of development in order to advance the marketing horizon up to 3 years, to conquer an addressable market of over one billion euros Valbiotis presents preclinical data on the plant-derived active substance TOTUM•854, designed to reduce blood pressure, at the Annual Joint Meeting of the European Society of […]

VALBIOTIS Obtains ISO 9001 Certification for Its Activities in “Design, Development and Production Control of Solutions for Preventing and Combating Metabolic and Cardiovascular Diseases”

LA ROCHELLE, France–(BUSINESS WIRE)–Regulatory News: VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / eligible for the PEA/SME), a French Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces that it has obtained ISO 9001 certification for its Quality Management System (QMS) deployed on its three sites. […]

VALBIOTIS Releases Its 2020 Annual Results

LA ROCHELLE, France–(BUSINESS WIRE)–Regulatory News: 2020 highlights and results Global strategic partnership with Nestlé Health Science for the development and marketing of TOTUM-63, a plant-based active substance with clinically proven metabolic health benefits in prediabetic subjects. Launch of REVERSE-IT, a global pivotal Phase II/III clinical trial of TOTUM-63 for reducing […]

VALBIOTIS Announces the First Patient’s First Visit in the Phase II HEART Clinical Study on TOTUM-070 and Steps up Its Research Program Against Hypercholesterolemia in 2021

The first subject, with blood LDL-cholesterol (“bad cholesterol”) levels greater than 130 mg/dL, has undergone the initial medical examination for the HEART protocol on the active substance TOTUM-070. The HEART study will include 120 people with elevated blood LDL-cholesterol, a risk factor for cardiovascular disease and the primary endpoint of […]

VALBIOTIS Authorized to Launch HEART, the Phase II Multi-center Clinical Study With TOTUM-070, for the Reduction of Blood LDL-cholesterol Levels

The favorable opinion of the CPP (French ethic committee) and authorization from the ANSM (French National Agency for the Safety of Medicines and Health Products) allow the operational launch of the HEART study. The HEART study will be conducted under the scientific expertise of Jean-Marie Bard, Professor and Hospital Practitioner […]

VALBIOTIS Presents the First Market Data on Untreated LDL-hypercholesterolemia For TOTUM-070, And Announces the Initiation of The Phase II Clinical Study HEART

TOTUM-070 is being developed particularly for individuals with untreated hypercholesterolemia, with LDL-cholesterol levels up to 190 mg/dL associated with moderate overall cardiovascular risk. It responds to an unmet medical need for this population; TOTUM-070 has high potential in the market for non-drug LDL-cholesterol products, which is estimated at 1.2 billion […]

VALBIOTIS Receives US and European TOTUM-070 Patent for Reducing Hypercholesterolemia

TOTUM-070 exclusivity guaranteed in the United States and in Europe for reducing blood LDL-cholesterol levels, a cardiovascular disease risk factor; Intellectual property rights protecting the composition of the TOTUM-070 active substance for food and pharmaceutical applications; A milestone in the further development of TOTUM-070, in the search for commercial partnerships […]

VALBIOTIS Accelerates Its Pipeline Clinical Development in New Indications: Cardiovascular and Hepatic Steatosis Risk Reduction

LA ROCHELLE, France–(BUSINESS WIRE)–Regulatory News: VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / PEA/ SME eligible), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the acceleration of its pipeline clinical development, of plant-derived active substances, in new indications: cardiovascular and hepatic steatosis risk. Building […]